These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 26188511)
41. Novel Role for Protein Inhibitor of Activated STAT 4 (PIAS4) in the Restriction of Herpes Simplex Virus 1 by the Cellular Intrinsic Antiviral Immune Response. Conn KL; Wasson P; McFarlane S; Tong L; Brown JR; Grant KG; Domingues P; Boutell C J Virol; 2016 May; 90(9):4807-4826. PubMed ID: 26937035 [TBL] [Abstract][Full Text] [Related]
42. TRIM5α is a SUMO substrate. Dutrieux J; Portilho DM; Arhel NJ; Hazan U; Nisole S Retrovirology; 2015 Mar; 12():28. PubMed ID: 25880753 [TBL] [Abstract][Full Text] [Related]
43. Role for SUMO modification in facilitating transcriptional repression by BKLF. Perdomo J; Verger A; Turner J; Crossley M Mol Cell Biol; 2005 Feb; 25(4):1549-59. PubMed ID: 15684403 [TBL] [Abstract][Full Text] [Related]
44. Ubiquitin-SUMO circuitry controls activated fanconi anemia ID complex dosage in response to DNA damage. Gibbs-Seymour I; Oka Y; Rajendra E; Weinert BT; Passmore LA; Patel KJ; Olsen JV; Choudhary C; Bekker-Jensen S; Mailand N Mol Cell; 2015 Jan; 57(1):150-64. PubMed ID: 25557546 [TBL] [Abstract][Full Text] [Related]
45. SUMO pathway components as possible cancer biomarkers. Mattoscio D; Chiocca S Future Oncol; 2015; 11(11):1599-610. PubMed ID: 26043214 [TBL] [Abstract][Full Text] [Related]
46. Ubc9 sumoylation regulates SUMO target discrimination. Knipscheer P; Flotho A; Klug H; Olsen JV; van Dijk WJ; Fish A; Johnson ES; Mann M; Sixma TK; Pichler A Mol Cell; 2008 Aug; 31(3):371-82. PubMed ID: 18691969 [TBL] [Abstract][Full Text] [Related]
47. Characterization of a novel posttranslational modification in neuronal nitric oxide synthase by small ubiquitin-related modifier-1. Watanabe M; Itoh K Biochim Biophys Acta; 2011 Jul; 1814(7):900-7. PubMed ID: 21545853 [TBL] [Abstract][Full Text] [Related]
48. SUMOylation of hypoxia-inducible factor-1alpha reduces its transcriptional activity. Berta MA; Mazure N; Hattab M; Pouysségur J; Brahimi-Horn MC Biochem Biophys Res Commun; 2007 Aug; 360(3):646-52. PubMed ID: 17610843 [TBL] [Abstract][Full Text] [Related]
49. SUMO: getting it on. Anckar J; Sistonen L Biochem Soc Trans; 2007 Dec; 35(Pt 6):1409-13. PubMed ID: 18031233 [TBL] [Abstract][Full Text] [Related]
50. Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs). Wu YC; Roark AA; Bian XL; Wilson VG Virology; 2008 Sep; 378(2):329-38. PubMed ID: 18619639 [TBL] [Abstract][Full Text] [Related]
51. Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. Ohshima T; Koga H; Shimotohno K J Biol Chem; 2004 Jul; 279(28):29551-7. PubMed ID: 15123625 [TBL] [Abstract][Full Text] [Related]
52. In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity. Yang WS; Campbell M; Kung HJ; Chang PC J Vis Exp; 2018 Jan; (131):. PubMed ID: 29443041 [TBL] [Abstract][Full Text] [Related]
53. Characterization of a C-Terminal SUMO-Interacting Motif Present in Select PIAS-Family Proteins. Lussier-Price M; Mascle XH; Cappadocia L; Kamada R; Sakaguchi K; Wahba HM; Omichinski JG Structure; 2020 May; 28(5):573-585.e5. PubMed ID: 32348746 [TBL] [Abstract][Full Text] [Related]
54. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Bernier-Villamor V; Sampson DA; Matunis MJ; Lima CD Cell; 2002 Feb; 108(3):345-56. PubMed ID: 11853669 [TBL] [Abstract][Full Text] [Related]
55. Casein kinase-2-mediated phosphorylation increases the SUMO-dependent activity of the cytomegalovirus transactivator IE2. Tripathi V; Chatterjee KS; Das R J Biol Chem; 2019 Oct; 294(40):14546-14561. PubMed ID: 31371453 [TBL] [Abstract][Full Text] [Related]
56. Protein inhibitor of activated STAT 1 (PIAS1) is identified as the SUMO E3 ligase of CCAAT/enhancer-binding protein β (C/EBPβ) during adipogenesis. Liu Y; Zhang YD; Guo L; Huang HY; Zhu H; Huang JX; Liu Y; Zhou SR; Dang YJ; Li X; Tang QQ Mol Cell Biol; 2013 Nov; 33(22):4606-17. PubMed ID: 24061474 [TBL] [Abstract][Full Text] [Related]
57. Phosphorylation of protein inhibitor of activated STAT1 (PIAS1) by MAPK-activated protein kinase-2 inhibits endothelial inflammation via increasing both PIAS1 transrepression and SUMO E3 ligase activity. Heo KS; Chang E; Takei Y; Le NT; Woo CH; Sullivan MA; Morrell C; Fujiwara K; Abe J Arterioscler Thromb Vasc Biol; 2013 Feb; 33(2):321-9. PubMed ID: 23202365 [TBL] [Abstract][Full Text] [Related]
58. SUMOylation of RORalpha potentiates transcriptional activation function. Hwang EJ; Lee JM; Jeong J; Park JH; Yang Y; Lim JS; Kim JH; Baek SH; Kim KI Biochem Biophys Res Commun; 2009 Jan; 378(3):513-7. PubMed ID: 19041634 [TBL] [Abstract][Full Text] [Related]
59. SUMO Modification Stabilizes Dengue Virus Nonstructural Protein 5 To Support Virus Replication. Su CI; Tseng CH; Yu CY; Lai MMC J Virol; 2016 May; 90(9):4308-4319. PubMed ID: 26889037 [TBL] [Abstract][Full Text] [Related]
60. Effect of endosulfan and bisphenol A on the expression of SUMO and UBC9. Yarahalli Jayaram V; Baggavalli S; Reddy D; Sistla S; Malempati R Drug Chem Toxicol; 2020 Nov; 43(6):637-644. PubMed ID: 30426790 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]